Tobacco Use

Abstract

Tobacco use is a type of behavior in which a person consumes tobacco, chiefly by smoking, taking in nicotine that acts on the brain's reward circuitry and sustains repeated use. Psychologists study it as a learned, reinforced behavior rather than a simple habit: nicotine strengthens the actions that deliver it, environmental cues come to trigger craving, and withdrawal makes continued use negatively reinforcing. This article explains what tobacco use is and how it is classified, how nicotine reinforcement and the three-stage addiction cycle maintain it, how dependence and craving are measured, and how cessation is understood as a staged process supported by pharmacological and behavioral treatment. It also sets out the global disease burden that makes tobacco use the leading preventable cause of death, and reviews current directions including real-time craving measurement and the contested role of electronic cigarettes.

Keywords: tobacco use, nicotine addiction, cue reactivity, smoking cessation, dependence

Tobacco use is the behavior that psychology addresses when it studies the most widespread preventable cause of death in the world. It is sustained not by weakness of will but by the pharmacology of nicotine acting through ordinary mechanisms of learning: nicotine is a positive reinforcer whose receptor target is now precisely known (Picciotto et al., 1998), and the behavior it supports is shaped by the same incentive and cue-learning processes that govern other motivated action (Robinson & Berridge, 1993). Understanding tobacco use therefore means treating it as a learned, reinforced, and measurable behavior, which is what makes it both tractable to science and responsive to treatment.

What Tobacco Use Is

Tobacco use is the consumption of tobacco products, most commonly by smoking cigarettes but also through cigars, pipes, waterpipes, and smokeless forms such as chewing tobacco and snuff. In the Medical Subject Headings vocabulary it is classified as a behavior, the broad category of observable activity, which places it alongside other patterns of action that psychology studies rather than among diseases or substances. What unites its forms is the delivery of nicotine, an alkaloid that reaches the brain within seconds of inhalation and drives the behavior that delivers it (Benowitz, 2010).

The reason tobacco use is a psychological topic and not merely a medical one is that it is a behavior under the control of its consequences. Nicotine is a positive reinforcer: in a landmark study, mice lacking the beta-2 subunit of the nicotinic acetylcholine receptor no longer self-administered nicotine, pinpointing the molecular target through which nicotine strengthens the actions that deliver it (Picciotto et al., 1998). On top of this direct reinforcement, repeated pairing of nicotine with the sights, smells, and rituals of smoking gives those cues incentive value, so that the behavior becomes organized around craving triggered by the environment (Robinson & Berridge, 1993). The demonstration below shows how reinforcement builds the behavior over repeated episodes.

How reinforcement builds the behavior

Each time a smoking action is followed by nicotine reaching the brain, the probability of repeating that action rises. Step through successive episodes to watch the behavior acquire. Switch reinforcement off to model the beta-2 nicotinic receptor knockout, in which nicotine is no longer reinforcing and the behavior never takes hold.

After 12 episodes, the probability of repeating the action is 86%. With nicotine reinforcing each action, the behavior climbs toward a high steady level.

Table 1 summarizes the forms tobacco use takes and the dimensions along which they differ, which matter both for exposure and for how dependence develops.

Types of Tobacco Use

In the MeSH hierarchy, tobacco use is the parent category and its narrower descriptors name the specific forms the behavior takes. MeSH is an indexing vocabulary rather than a theoretical taxonomy, so these subtypes reflect how the literature is catalogued, and the categories are not mutually exclusive: a person may both smoke and use a smokeless product. The site currently covers the principal child descriptor as its own article.

- Tobacco Smoking — The inhalation of smoke from burning tobacco, the dominant form of tobacco use worldwide and the form responsible for most of its disease burden.

Tobacco smoking is distinguished from smokeless use chiefly by combustion, which produces the tar and carbon monoxide that drive most smoking-related disease while nicotine drives the dependence common to all forms. Because smoking delivers nicotine to the brain especially rapidly, it is also the form most strongly associated with the development of dependence.

How Nicotine Maintains the Behavior

Tobacco use persists because nicotine engages the brain's reward and stress systems in a self-perpetuating cycle. Koob and Volkow described addiction as a three-stage recurring loop: a binge/intoxication stage in which the drug is rewarding and cues are learned, a withdrawal/negative-affect stage in which absence of the drug produces dysphoria and irritability, and a preoccupation/anticipation stage in which craving and impaired control drive a return to use (Koob & Volkow, 2016). Across repeated cycles the balance shifts: positive reinforcement from the drug's pleasurable effects gives way to negative reinforcement, in which smoking primarily relieves the discomfort of withdrawal.

The incentive-sensitization account adds why cues become so powerful. Robinson and Berridge argued that repeated drug use sensitizes a neural 'wanting' system distinct from the 'liking' system, so that drug-associated cues come to command attention and trigger craving even when the drug itself is no longer especially pleasurable (Robinson & Berridge, 1993). This dissociation explains a familiar clinical paradox: smokers often report that cigarettes bring little pleasure yet feel intensely drawn to them, particularly in the presence of smoking cues. The onset of dependence can be surprisingly rapid, and need not wait for heavy daily use; DiFranza and colleagues documented symptoms of loss of autonomy over tobacco in youth after only intermittent exposure (DiFranza et al., 2007).

Measuring Dependence and Craving

Because tobacco use is a behavior, it can be measured, and psychology has developed instruments at several levels. Dependence itself is quantified with brief validated scales, the most widely used being the Fagerstrom Test for Nicotine Dependence, which scores features such as how soon after waking a person smokes and how many cigarettes they consume (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991). Time to the first cigarette of the day is an especially informative single item because it indexes the overnight drop in nicotine and the urgency of replacing it.

Craving is measured through cue reactivity, the heightened physiological and subjective response that drug cues provoke. Carter and Tiffany's meta-analysis established that across drug classes, including tobacco, drug-related cues reliably elicit self-reported craving, confirming the central role of learned cues in addiction (Carter & Tiffany, 1999). Because craving is momentary and context-bound, it is also captured in daily life by ecological momentary assessment, in which smokers report urges and smoking in real time on portable devices, revealing patterns that retrospective questionnaires miss (Shiffman, Stone, & Hufford, 2008). The demonstration below shows how a smoking cue raises craving and how that reactivity subsides.

Cue reactivity: a trigger raises craving, then it fades

A smoking cue, such as the sight of a lighter, provokes a sharp rise in craving that then subsides if no cigarette follows. Toggle the cue on or off and adjust how strongly the cue has been learned. A stronger learned association produces a larger spike, but the craving still decays back toward baseline over time.

Peak craving reaches 80 on a 0-to-100 scale, then decays back toward the baseline of 20 as the cue goes unreinforced. This reactivity is the learned response that cue-exposure treatments aim to extinguish.

Quitting and Its Treatment

Stopping tobacco use is best understood not as a single decision but as movement through stages. Prochaska and DiClemente's transtheoretical model, developed in large part from studies of smokers, describes change as progress through precontemplation, contemplation, preparation, action, and maintenance, with relapse a normal part of the cycle rather than a failure (Prochaska & DiClemente, 1983). The model reframes a lapse as a return to an earlier stage from which the person can advance again, and it matches intervention to readiness rather than pushing every smoker to act at once.

Treatment works on both the pharmacological and behavioral sides of the behavior. Nicotine replacement therapy, which supplies nicotine without the combustion products of smoking, substantially increases the chance of quitting; a Cochrane review of many trials found that it raises long-term quit rates by roughly half to three-quarters relative to control (Hartmann-Boyce, Chepkin, Ye, Bullen, & Lancaster, 2018). The demonstration below lets the user combine pharmacological and behavioral support to see their joint effect on the predicted quit rate.

Combining treatments: the odds-multiplier model

The baseline six-month quit rate with brief advice alone is 10 percent, so the odds of quitting are 0.111. Nicotine replacement therapy multiplies those odds by 1.6, and adding structured behavioral support multiplies them by a further 1.5. Toggle each support to see the predicted quit rate, converted from odds back to a percentage.

Odds of quitting: 0.111, a predicted quit rate of 10.0%. Selecting both supports multiplies the baseline odds by 1.6 and 1.5 in turn (0.111 × 1.6 × 1.5 = 0.267), roughly doubling the quit rate from 10 to 21 percent, which is why guidelines recommend offering medication and behavioral support together.

Worked Example

Consider the odds of successfully quitting with different supports, using illustrative numbers consistent in form with the trial literature. Suppose the baseline six-month quit rate with brief advice alone is 10 percent, so the odds of quitting are 0.10 / 0.90 = 0.111. Nicotine replacement therapy multiplies the odds of quitting by about 1.6, and adding structured behavioral support multiplies them by a further 1.5, with the two assumed to act independently. Using nicotine replacement alone gives odds of 0.111 x 1.6 = 0.178, which corresponds to a quit rate of 0.178 / (1 + 0.178) = 15.1 percent. Adding behavioral support multiplies the odds again: 0.178 x 1.5 = 0.267, a quit rate of 0.267 / (1 + 0.267) = 21.1 percent. The combination therefore roughly doubles the baseline quit rate, from 10 to 21 percent, which is why guidelines recommend offering medication and behavioral support together rather than either alone. The demonstration above uses exactly this odds-multiplier model, so selecting both supports multiplies the baseline odds by 1.6 and 1.5 in turn and converts the result back to a percentage.

Key Researchers

Neal L. Benowitz

(living). Clinical pharmacologist at the University of California, San Francisco; his work established how nicotine is absorbed, metabolized, and dosed, and frames the pharmacology of nicotine addiction and its treatment. ORCID

Kent C. Berridge

(b. 1957). Psychologist at the University of Michigan; with Terry Robinson he developed the incentive-sensitization theory distinguishing drug 'wanting' from 'liking.' Wikipedia

Jamie Hartmann-Boyce

(living). Health scientist at the University of Massachusetts Amherst and the University of Oxford; she leads the Cochrane systematic reviews of nicotine replacement therapy and electronic cigarettes for cessation. ORCID

George F. Koob

(living). Neuroscientist and Director of the National Institute on Alcohol Abuse and Alcoholism; he developed the three-stage neurocircuitry model of the addiction cycle. Wikipedia

James O. Prochaska

(1942-2023). Psychologist at the University of Rhode Island; he originated the transtheoretical stages-of-change model from studies of how smokers quit. Wikipedia

Nora D. Volkow

(living). Psychiatrist and Director of the National Institute on Drug Abuse; her brain-imaging research mapped the dopamine systems of addiction underpinning the neurocircuitry model. ORCID

Robert West

(living). Health psychologist at University College London; he directs the Smoking Toolkit Study and has synthesized the determinants, prevalence, and treatment of smoking. UCL

Discussion

Tobacco use is a model case for how psychology analyzes a harmful behavior. It is maintained by a well-characterized reinforcer acting on identified neural targets (Picciotto et al., 1998; Benowitz, 2010), shaped by cue learning that gives the environment control over craving (Robinson & Berridge, 1993; Carter & Tiffany, 1999), and organized over time into a recurring cycle that recruits reward and stress systems in turn (Koob & Volkow, 2016). Each of these facts is also a lever for intervention, which is why the same science that explains why tobacco use is so persistent also explains why it is treatable.

The scale of the problem is what gives this analysis its urgency. The Global Burden of Disease study estimated that smoking remains one of the leading risk factors for death and disability worldwide, responsible for millions of deaths each year despite decades of declining prevalence in many countries (GBD 2019 Tobacco Collaborators, 2021). Because cessation at any age substantially reduces that risk, and because treatment roughly doubles the chance of quitting (Hartmann-Boyce et al., 2018), the behavioral science of tobacco use translates directly into one of the largest available gains in public health (West, 2017).

Current Directions

Several fronts are active. The measurement of craving has moved from the laboratory into daily life, and ecological momentary assessment now allows researchers to track urges, triggers, and lapses as they happen, sharpening both theory and relapse-prevention tools (Shiffman, Stone, & Hufford, 2008). The most contested current question is the role of electronic cigarettes, which deliver nicotine without combustion: a Cochrane review concluded that nicotine e-cigarettes help more people stop smoking than traditional nicotine replacement therapy, while their long-term safety and their effect on youth uptake remain under active debate (Lindson et al., 2024). A third strand concerns prevention, where evidence that dependence can begin after very limited exposure in adolescence has shifted attention toward early intervention (DiFranza et al., 2007). Across these fronts the broad research program is to connect the neuroscience of nicotine reinforcement to the population science of who starts, who quits, and why (West, 2017).

Common Misconceptions

Tobacco use is just a bad habit that willpower can break.

It is a reinforced behavior maintained by nicotine acting on identified reward circuitry, which is why most unaided quit attempts fail and treatment helps (Benowitz, 2010).

Smokers keep smoking because they enjoy it.

Incentive-sensitization shows that 'wanting' can grow while 'liking' fades, so craving triggered by cues can persist even when the pleasure is gone (Robinson & Berridge, 1993).

Only heavy daily smokers become dependent.

Symptoms of lost autonomy over tobacco can appear in youth after only intermittent use, well before daily smoking is established (DiFranza et al., 2007).

Glossary

Addiction cycle.

The recurring three-stage loop of binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation that maintains drug use.

Craving.

A strong subjective urge to use tobacco, often triggered by cues and measured by self-report and physiological reactivity.

Cue reactivity.

The heightened physiological and subjective response to drug-associated cues, a reliable marker of learned craving.

Dependence.

A state in which continued tobacco use is driven by reinforcement and withdrawal, quantified by scales such as the Fagerstrom test.

Ecological momentary assessment.

A method of sampling behavior and craving in real time and in natural settings, reducing reliance on retrospective recall.

Electronic cigarette.

A device that delivers nicotine as a vapor without combustion, studied as a cessation aid and a harm-reduction option.

Fagerstrom test.

A brief validated questionnaire scoring nicotine dependence from features such as time to the first cigarette of the day.

Incentive sensitization.

The theory that repeated drug use sensitizes a 'wanting' system, making cues trigger craving independently of pleasure.

Negative reinforcement.

The strengthening of smoking by the removal of an aversive state, such as the relief of withdrawal discomfort.

Nicotine replacement therapy.

Treatment that supplies nicotine without combustion products, raising the chance of quitting smoking.

Nicotine.

The addictive alkaloid in tobacco that reaches the brain within seconds and acts as a positive reinforcer.

Positive reinforcement.

The strengthening of a behavior by a rewarding consequence; nicotine reinforces the actions that deliver it.

Transtheoretical model.

A staged account of behavior change, from precontemplation through maintenance, developed from studies of smokers.

Withdrawal.

The aversive physical and emotional state that follows cessation of nicotine, driving negatively reinforced relapse.

Frequently Asked Questions

What is tobacco use?

It is the behavior of consuming tobacco products, chiefly by smoking, which delivers nicotine to the brain and is classified in MeSH as a type of behavior (Benowitz, 2010).

Why is tobacco use so hard to stop?

Nicotine is a positive reinforcer acting on identified brain receptors, and over time smoking also becomes negatively reinforced by the relief of withdrawal, so stopping means overcoming both (Picciotto et al., 1998; Koob & Volkow, 2016).

What is the difference between wanting and liking a cigarette?

Incentive-sensitization theory holds that repeated use sensitizes a 'wanting' system separate from the 'liking' system, so smokers can crave cigarettes intensely even when they bring little pleasure (Robinson & Berridge, 1993).

How is nicotine dependence measured?

It is scored with brief validated instruments, most commonly the Fagerstrom Test for Nicotine Dependence, which weighs features such as how soon after waking a person smokes (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991).

What is cue reactivity?

It is the heightened craving and physiological response that smoking-related cues provoke; a meta-analysis confirmed that such cues reliably elicit craving across drug classes (Carter & Tiffany, 1999).

Does nicotine replacement therapy work?

Yes; a Cochrane review of many trials found that nicotine replacement therapy raises long-term quit rates by roughly half to three-quarters relative to control (Hartmann-Boyce, Chepkin, Ye, Bullen, & Lancaster, 2018).

Can electronic cigarettes help people quit?

A Cochrane review concluded that nicotine e-cigarettes help more people stop smoking than traditional nicotine replacement therapy, though their long-term effects remain under debate (Lindson et al., 2024).

How many people does tobacco use harm?

Smoking remains one of the leading risk factors for death worldwide, responsible for millions of deaths each year and making it the leading preventable cause of death (GBD 2019 Tobacco Collaborators, 2021).

References